Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BFRA

Biofrontera (BFRA) Stock Price, News & Analysis

Biofrontera logo

About Biofrontera Stock (NASDAQ:BFRA)

Advanced Chart

Key Stats

Today's Range
$2.51
$2.78
50-Day Range
$2.50
$3.60
52-Week Range
$2.09
$7.54
Volume
7,263 shs
Average Volume
27,512 shs
Market Capitalization
$73.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Receive BFRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

BFRA Stock News Headlines

Biofrontera AG’s Q1 2025 Earnings Call Highlights
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
Q1 2025 Biofrontera Inc Earnings Call
See More Headlines

BFRA Stock Analysis - Frequently Asked Questions

Biofrontera AG (NASDAQ:BFRA) issued its quarterly earnings data on Wednesday, November, 24th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.03. The company had revenue of $6.34 million for the quarter. Biofrontera had a negative trailing twelve-month return on equity of 93.31% and a negative net margin of 59.44%.

Biofrontera (BFRA) raised $18 million in an initial public offering (IPO) on Wednesday, February 14th 2018. The company issued 1,500,000 shares at a price of $11.00-$13.00 per share. Benchmark acted as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include AMC Entertainment (AMC), AC Immune (ACIU), Adaptimmune Therapeutics (ADAP), ADMA Biologics (ADMA), Ashford Hospitality Trust (AHT), Akebia Therapeutics (AKBA) and Assembly Biosciences (ASMB).

Company Calendar

Last Earnings
11/24/2021
Today
5/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BFRA
Employees
138
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.88 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$36.19 million
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
7.43

Miscellaneous

Free Float
N/A
Market Cap
$73.73 million
Optionable
Not Optionable
Beta
1.02
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:BFRA) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners